Biotech investors always seem to be looking for the next big thing. These days, many are going under the hood of the CAR-T. CAR-T is short for chimeric antigen receptor T-cell therapy, a version of immunotherapy, which deploys the patient’s own immune system to fight cancer. First developed in academic labs, CAR-T therapies have been picked up by big pharma Novartis (NVS) as well as a number of small startups. Kite Pharma (KITE), Bluebird Bio
Shares of biotech Vanda Therapeutics (VNDA) soared nearly 25% at one point on the stock market today, to an almost five-month high, after the company settled a lawsuit with its Big Pharma partner and regained full rights to schizophrenia drug Fanapt. Late Monday, Vanda said Novartis (NVS) had agreed to transfer U.S. and Canadian rights to Fanapt to Vanda and make a $25 million equity investment in the firm. Vanda had been drawing just a 10%
Shares of biotech Vanda Therapeutics (VNDA) soared nearly 25% at one point on the stock market today, to an almost five-month high, after the company settled a lawsuit with its Big Pharma partner and regained full rights to schizophrenia drug Fanapt. Late Monday, Vanda said Novartis (NVS) had agreed to transfer U.S. and Canadian rights to Fanapt to Vanda and make a $25 million equity investment in the firm. Vanda had been drawing just a 10%